Ankylosing spondylitis is classified under the umbrella of axial spondyloarthritis (axSpA). Treatment goals focus on reducing systemic inflammation, controlling pain, maintaining spinal flexibility, preventing irreversible structural damage, and preserving functional independence. Management involves a multimodal approach guided by clinical disease activity measures and objective markers of inflammation.

Management of ankylosing spondylitis relies on a phased clinical management protocol. First, baseline disease activity is measured using validated tools like the Ankylosing Spondylitis Disease Activity Score (ASDAS). Initial pharmacological therapy consists of full-dose non-steroidal anti-inflammatory drugs (NSAIDs) taken continuously. Physical therapy protocols emphasize extension exercises, spinal range-of-motion routines, and hydrotherapy. When NSAID response is inadequate, clinicians initiate targeted biologic agents, such as TNF inhibitors or IL-17 inhibitors, monitored through periodic clinical evaluations and serial inflammatory biomarker assays.

Evidence-based management of ankylosing spondylitis yields significant clinical benefits, including marked reductions in spinal stiffness, control of chronic nocturnal back pain, preservation of spinal range of motion, and suppression of systemic inflammatory markers. Long-term compliance with targeted therapeutic protocols decreases the rate of radiographic spinal progression and reduces disability.

Recovery and disease control in ankylosing spondylitis follow an ongoing, non-linear timeline. Symptomatic relief from anti-inflammatory therapies often occurs within days to weeks, while optimal clinical response from biologic agents typically unfolds over 12 to 24 weeks. Long-term functional retention relies on lifetime maintenance of physical exercise and structured medical oversight.

Ankylosing spondylitis management addresses axial inflammatory arthritis, sacroiliitis (inflammation of the sacroiliac joints), enthesitis (inflammation where tendons or ligaments insert into bone), peripheral arthritis, and systemic extra-articular manifestations including anterior uveitis (eye inflammation), inflammatory bowel disease, and psoriasis.

Preparation for therapy involves screening for chronic underlying infections, including latent tuberculosis and hepatitis B/C, prior to biological initiation. Baseline imaging with radiographs or magnetic resonance imaging (MRI) of the sacroiliac joints and spine is performed. Routine laboratory assessments include erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and baseline renal and hepatic function testing.

Potential complications of treatment include gastrointestinal ulceration and cardiovascular stress from prolonged non-selective NSAID exposure. Biologic and targeted synthetic therapies carry risks of opportunistic infections, localized injection-site reactions, cytopenias, elevated liver enzyme levels, and paradoxical inflammatory manifestations such as new-onset psoriasis or inflammatory bowel flare-ups.

The clinical journey for managing ankylosing spondylitis begins with early diagnosis through clinical evaluation, magnetic resonance imaging, and inflammatory laboratory panels. Patients then enter a structured medical management phase initiating first-line anti-inflammatory agents alongside individualised physical therapy. If disease activity remains elevated, protocol escalation to targeted biologic or synthetic disease-modifying therapies occurs, supported by continuous monitoring of functional status and spinal mobility.